Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24659688 | 0.95 | KDM1A (0.56) | KDM1AGPR119BCDIN3DCETPJAK2 | |
| SCHEMBL16808849 | 0.95 | KDM1A (0.56) | KDM1AGPR119BCDIN3DCETPJAK2 | |
| SCHEMBL16797266 | 0.90 | KDM1A (0.55) | KDM1AGPR119EGLN2 | |
| SCHEMBL16797325 | 0.87 | GPR119 (0.52) | KDM1AGPR119JAK2JAK3PTK2 | |
| SCHEMBL17686615 | 0.85 | KDM1A (0.48) | KDM1AGPR119CETPJAK2JAK3 | |
| SCHEMBL17559071 | 0.84 | KDM1A (0.66) | KDM1AJAK2JAK3EGLN2VNN1 | |
| SCHEMBL16797362 | 0.83 | KDM1A (0.63) | KDM1AJAK2JAK3VNN1 | |
| SCHEMBL30034274 | 0.83 | IDO1 (0.45) | KDM1AGPR119CETPJAK2JAK3 | |
| SCHEMBL16808869 | 0.82 | GPR119 (0.46) | GPR119CETPEGLN2 | |
| SCHEMBL16797316 | 0.81 | MAPK1 (0.50) | KDM1AGPR119EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257591-A2 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3080100-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3189038-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-10864202-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200108052-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-10131664-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9944636-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9822119-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. | 2016-10-20 | — | — | US | disclosed |
| EP-3080100-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2015089192-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885GPR119 2640/4885BCDIN3D 179/4885 |
| US-20200108052-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885GPR119 2640/4885BCDIN3D 179/4885 |
| US-10864202-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885GPR119 2640/4885BCDIN3D 179/4885 |
| US-10131664-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885GPR119 2640/4885BCDIN3D 179/4885 |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885GPR119 2640/4885BCDIN3D 179/4885 |
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885GPR119 2640/4885BCDIN3D 179/4885 |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885GPR119 2640/4885BCDIN3D 179/4885 |
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885GPR119 2640/4885BCDIN3D 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.